IND Swift Limited — Clarithromycin Exporter Profile
Indian Pharmaceutical Exporter · #10 for Clarithromycin · $2.9M export value · DGFT Verified
IND Swift Limited is the #10 Indian exporter of Clarithromycin with $2.9M in export value and 124 verified shipments. IND Swift Limited holds a 2.9% market share in Clarithromycin exports across 23 countries. The company exports 13 pharmaceutical products worth $36.7M across 9 therapeutic categories.
IND Swift Limited — Clarithromycin Export Profile: Buyers & Destinations
Where Does IND Swift Limited Export Clarithromycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| TANZANIA | $444.6K | 20 | 18.6% |
| POLAND | $246.9K | 6 | 10.4% |
| PHILIPPINES | $190.7K | 5 | 8.0% |
| KENYA | $159.8K | 10 | 6.7% |
| VIETNAM | $150.0K | 4 | 6.3% |
| BELGIUM | $144.3K | 5 | 6.0% |
| BULGARIA | $133.7K | 8 | 5.6% |
| SPAIN | $127.5K | 4 | 5.3% |
| UNITED KINGDOM | $120.8K | 5 | 5.1% |
| VIETNAM, DEMOCRATIC REP. OF | $113.1K | 6 | 4.7% |
IND Swift Limited exports Clarithromycin to 24 countries. The largest destination is TANZANIA accounting for 18.6% of IND Swift Limited's Clarithromycin shipments, followed by POLAND (10.4%) and PHILIPPINES (8.0%). These destinations reflect IND Swift Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Clarithromycin from IND Swift Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DANANG PHARMACEUTICAL | VIETNAM | $263.1K | 10 |
| POLPHARMA SA | POLAND | $246.9K | 6 |
| PLANET PHARMACEUTICAL LTD. | TANZANIA | $214.4K | 6 |
| SURGIPHARM LIMITED | KENYA | $159.8K | 10 |
| PLANET PHARMACEUTICALS LTD. | TANZANIA | $148.1K | 9 |
| LIVLINA | BELGIUM | $144.3K | 5 |
| MORNINGSIDE PHARMACEUTICALS LIMITED | UNITED KINGDOM | $120.8K | 5 |
| NEW COUNTRY HEALTHCARE LLC | UNITED ARAB EMIRATES | $101.0K | 4 |
| UNILAB, INC. | PHILIPPINES | $91.3K | 2 |
| TCHAIKAPHARMA HIGH QUALITY | BULGARIA | $83.3K | 4 |
IND Swift Limited supplies Clarithromycin to 36 buyers globally. The largest buyer is DANANG PHARMACEUTICAL (VIETNAM), followed by POLPHARMA SA (POLAND) and PLANET PHARMACEUTICAL LTD. (TANZANIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Clarithromycin Export Value and How Much Does IND Swift Limited Contribute?
India exported $61.2M worth of Clarithromycin through 3,576 shipments from 334 suppliers to 144 countries, serving 811 buyers globally. IND Swift Limited contributes $2.9M to this total, accounting for 2.9% of India's Clarithromycin exports. IND Swift Limited ships Clarithromycin to 24 countries through 36 buyers.
What Is the Average Shipment Value for IND Swift Limited's Clarithromycin Exports?
IND Swift Limited's average Clarithromycin shipment value is $23.0K per consignment, based on 124 shipments totaling $2.9M. The largest destination is TANZANIA (18.6% of IND Swift Limited's Clarithromycin exports).
How Does IND Swift Limited Compare to Other Indian Clarithromycin Exporters?
IND Swift Limited ranks #10 among 334 Indian Clarithromycin exporters with a 2.9% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($15.4M), MICRO LABS LIMITED ($15.4M), AUROBINDO PHARMA LTD ($7.8M). IND Swift Limited processed 124 shipments to 23 destination countries.
What Clarithromycin Formulations Does IND Swift Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| KLABION UNO 500 MG(Clarithromycin Extend | $121.3K | 3 |
| CLARIE OD 500 MG(CLARITHROMYCIN EXTENDEDRELEASE TABLETS USP) BATCH NO.EV10524,EV10624,EV10724 MFG.05.04.2024 EXP.04.04. | $97.1K | 3 |
| SWIFT OD 500MG(CLARITHROMYCIN EXTENDED-R | $81.0K | 2 |
| CLARIE OD (CLARITHROMYCIN EXTENDED -RELEASE TABLETS USP ) B.N: EV12424 ,EV12524,MFG: DEC2024 EXP: NOV2028 | $79.5K | 2 |
| CLARIE OD (CLARITHROMYCIN EXTENDED -RELEASE TABLETS USP ) B.N: EV12624,EV12724,MFG: DEC2024 EXP: NOV2028 | $70.9K | 2 |
| CLARITHROMYCINE UNO EG 500MG TABSS(CLARI | $68.1K | 2 |
| CLARIE OD (CLARITHROMYCIN EXTENDED -RELEASE TABLETS USP ) BATCH NO: EV12523 MFG:DEC2023 EXP: NOV2027 | $64.0K | 2 |
| CLARITHROMYCINE UNO EG 500 MG(CLARITHROM | $60.9K | 2 |
| KLACAR XL 500MG (CLARITHROMYCIN PROLONGED RELEASE TABLETS 500MG) BATCH NO WX10124, WX10224 MFG MAR2024 EXP FEB2028 | $60.4K | 3 |
| CLOROM XL 500MG(CLARITHROMYCIN 500MG PROLONGED RELEASE TABLETS)B.NO.:TF10124 & TF10224 M:APR.2024 E:MAR.2027(29586X1X7T) | $51.8K | 3 |
IND Swift Limited exports 74 distinct Clarithromycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is KLABION UNO 500 MG(Clarithromycin Extend with 3 shipments worth $121.3K.
How Does IND Swift Limited Compare to Nearest Clarithromycin Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | CAPLIN POINT LABORATORIES LIMITED | $5.5M | 110 | 10 | $50.0K |
| 7 | AJANTA PHARMA LIMITED | $4.0M | 109 | 9 | $36.6K |
| 10 | IND SWIFT LIMITED ★ | $2.9M | 124 | 23 | $23.0K |
| 5 | CIPLA LIMITED | $2.1M | 43 | 6 | $50.0K |
| 6 | WEXFORD LABORATORIES PRIVATE LIMITED | $1.8M | 35 | 4 | $50.0K |
IND Swift Limited ranks #10 among 334 Indian Clarithromycin exporters. Average shipment value of $23.0K compared to the market average of $183.3K. The closest competitors by value are CAPLIN POINT LABORATORIES LIMITED and AJANTA PHARMA LIMITED.
Which Indian Ports Ship Clarithromycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 365 | 10.2% |
| DELHI AIR CARGO ACC (INDEL4) | 296 | 8.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 282 | 7.9% |
| DELHI AIR | 258 | 7.2% |
| NHAVA SHEVA SEA (INNSA1) | 229 | 6.4% |
| JNPT/ NHAVA SHEVA SEA | 156 | 4.4% |
| JNPT | 125 | 3.5% |
| DHANNAD ICD | 124 | 3.5% |
Geopolitical & Trade Policy Impact on IND Swift Limited's Clarithromycin Exports
Ind-Swift Laboratories' export operations have been influenced by recent geopolitical developments. The Israel-Iran conflict has heightened security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the company's logistics and cost structures. (livemint.com)
Conversely, the India–European Union Free Trade Agreement (India–EU FTA), concluded in January 2026, is poised to benefit Indian pharmaceutical exporters. The agreement eliminates tariffs on most European pharmaceutical imports, enhancing the competitiveness of Indian products in the EU market. This development presents an opportunity for Ind-Swift Laboratories to expand its footprint in Europe. (en.wikipedia.org)
In the United States, the reshoring of pharmaceutical manufacturing and potential imposition of tariffs on imports pose challenges for Indian exporters. While there are currently no import duties on Indian pharmaceutical products entering the US, the introduction of tariffs could affect the profitability of low-margin generic drugs, potentially leading to market exits. (cfo.economictimes.indiatimes.com)
IND Swift Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Indian pharmaceutical exporters. Ind-Swift Laboratories has demonstrated a commitment to quality by adhering to Good Manufacturing Practices (GMP) as stipulated by the US FDA, WHO, and EU authorities. The company's manufacturing facilities in Punjab and Jammu have been inspected and approved by these regulatory bodies, facilitating access to regulated markets.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous investment in quality systems and supply chain transparency. Ind-Swift Laboratories' focus on high-margin formulations underscores the importance of maintaining stringent quality standards to meet global regulatory requirements and sustain market access.
About IND Swift Limited
IND Swift Limited exports 13 products worth $36.7M. Beyond Clarithromycin, top products include Fexofenadine, Ramipril, Loratadine, Ezetimibe, Terbinafine. View the complete IND Swift Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Clarithromycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Clarithromycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: IND Swift Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 124 individual customs records matching IND Swift Limited exporting Clarithromycin, covering 74 formulations to 24 countries via 36 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 144+ countries, 811+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Clarithromycin Export Data from IND Swift Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for IND Swift Limited's Clarithromycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
IND Swift Limited
Full Company Profile →
13 products · $36.7M total trade · 9 categories
Clarithromycin Stats
Company Overview
Top Products by IND Swift Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for IND Swift Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Clarithromycin. For current shipment-level data, contact TransData Nexus.